Biotechnology News and Research

RSS

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

BioTime first-quarter total revenue up 159% to $767,127

BioTime, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

International Stem Cell signs definitive agreement with Socius CG II

International Stem Cell Corporation, www.intlstemcell.com, today announced it has entered into a definitive agreement dated May 4, 2010 with Socius CG II, Ltd., pursuant to which Socius has committed to purchase a single tranche of up to $10 million in non-convertible Series F Preferred Stock from ISCO.

5 May 2010

Micromet reports total revenues of $6.3 million for first-quarter 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010.

5 May 2010

Survey reveals need for educating U.S. women about stroke symptoms

Although more than 425,000 women suffer from stroke each year, 55,000 more than men, a new survey showed that women may be dramatically underestimating their risk of this medical emergency, the third leading cause of death in the United States. Only 27 percent of women who were surveyed could name more than two of the six primary stroke symptoms. Moreover, seven out of 10 women who were surveyed said they are not aware they are more likely than men to have a stroke, and were not at all or only somewhat knowledgeable about risk factors.

5 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010

Scientists develop new web-based algorithm techniques to identify DNA sequences

Life is almost unbearably complex. Humans and mice, frogs and flies toggle genes on and off in dizzying combinations and sequences during their relentless march from embryo to death. Now scientists seeking to understand the machinations of the proteins behind the genomic wizard's screen have a powerful new tool at their disposal, courtesy of researchers at the Stanford University School of Medicine.

5 May 2010

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

Palatin Technologies, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors.

5 May 2010

Particle Sciences extends collaboration with Microfluidics to implement MRT system

Particle Sciences and Microfluidics extended their collaboration with the placement of the newly-announced Microfluidics Reaction Technology system at Particle Sciences.

5 May 2010

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion

Pfizer Inc. today reported financial results for first-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth operations are reflected in first-quarter 2010 results, but not in first-quarter 2009 results. First-quarter 2010 revenues were $16.8 billion, an increase of 54% compared with $10.9 billion in the year-ago quarter.

5 May 2010

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, are providing their second bi-weekly Default Status Report under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

5 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010